Summary
238.24 0.88(0.37%)10/04/2024
Becton, Dickinson And Co. (BDX)
Becton, Dickinson And Co. (BDX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.37 | -1.30 | 0.87 | 4.60 | -1.98 | -8.27 | 1.90 | 20,262.39 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 238.24 | |
| Open | 237.62 | |
| High | 238.91 | |
| Low | 236.69 | |
| Volume | 565,324 | |
| Change | 0.88 | |
| Change % | 0.37 | |
| Avg Volume (20 Days) | 1,065,575 | |
| Volume/Avg Volume (20 Days) Ratio | 0.53 | |
| 52 Week Range | 218.75 - 269.52 | |
| Price vs 52 Week High | -11.61% | |
| Price vs 52 Week Low | 8.91% | |
| Range | 0.26 | |
| Gap Up/Down | -2.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 68,581 | |
| EBIDTA | 5,070,000,128 | |
| PE Ratio | 50.4647 | |
| PEG Ratio | 1.3383 | |
| WallStreet Target Price | 275.27 | |
| Book Value | 88.7420 | |
| Earnings Per Share | 4.6700 | |
| EPS Estimate Current Quarter | 2.9700 | |
| EPS Estimate Next Quarter | 3.4300 | |
| EPS Estimate Current Year | 13.0400 | |
| EPS Estimate Next Year | 14.2500 | |
| Diluted EPS (TTM) | 4.6700 | |
| Revenues | ||
| Profit Marging | 0.0676 | |
| Operating Marging (TTM) | 0.1643 | |
| Return on asset (TTM) | 0.0320 | |
| Return on equity (TTM) | 0.0537 | |
| Revenue TTM | 19,715,999,744 | |
| Revenue per share TTM | 68.1720 | |
| Quarterly Revenue Growth (YOY) | 0.0460 | |
| Quarterly Earnings Growth (YOY) | 0.2090 | |
| Gross Profit (TTM) | 8,823,000,000 | |
| Dividends | ||
| Dividend Share | 3.7200 | |
| Dividend Yield | 0.0161 | |
| Valuations | ||
| Trailing PE | 50.4647 | |
| Forward PE | 17.3611 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.6819 | |
| Revenue Enterprise Value | 4.2514 | |
| EBITDA Enterprise Value | 19.3484 | |
| Shares | ||
| Shares Outstanding | 289,006,016 | |
| Shares Float | 288,304,175 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.31 | |
| Institutions (%) | 88.00 | |
10/03 13:10 EST - zacks.com
Three Reasons Why You Should Hold BDX Stock in Your Portfolio Now
BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
Three Reasons Why You Should Hold BDX Stock in Your Portfolio Now
BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
10/02 17:00 EST - prnewswire.com
BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation
No admission of liability or wrongdoing; settlement structured to eliminate uncertainty for all stakeholders related to settled cases. Settlement amount within current product litigation reserve and will be paid out over a multi-year period.
BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation
No admission of liability or wrongdoing; settlement structured to eliminate uncertainty for all stakeholders related to settled cases. Settlement amount within current product litigation reserve and will be paid out over a multi-year period.
09/27 09:19 EST - seekingalpha.com
My Best Dividend Aristocrats For October 2024
The ProShares S&P 500 Dividend Aristocrats ETF extends it's good form in the second half of 2024, adding a gain of 3.69% in August. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 38 months of tracking these strategies, all 3 strategies are generating a CAGR superior to NOBL while also offering a higher starting dividend yield.
My Best Dividend Aristocrats For October 2024
The ProShares S&P 500 Dividend Aristocrats ETF extends it's good form in the second half of 2024, adding a gain of 3.69% in August. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 38 months of tracking these strategies, all 3 strategies are generating a CAGR superior to NOBL while also offering a higher starting dividend yield.
09/26 06:50 EST - prnewswire.com
New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion
FRANKLIN LAKES, N.J. , Sept. 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data that highlights how its advanced artificial intelligence technology can help health systems better identify incidents of controlled substance diversion in the operating room.
New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion
FRANKLIN LAKES, N.J. , Sept. 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data that highlights how its advanced artificial intelligence technology can help health systems better identify incidents of controlled substance diversion in the operating room.
09/24 15:08 EST - youtube.com
Why Matrix CIO is chasing Becton Dickinson and US Bancorp
David Katz, chief investment officer at Matrix Asset Advisors, joins 'The Exchange' to discuss his picks in the markets, how to position for the future, and more.
Why Matrix CIO is chasing Becton Dickinson and US Bancorp
David Katz, chief investment officer at Matrix Asset Advisors, joins 'The Exchange' to discuss his picks in the markets, how to position for the future, and more.
09/20 09:35 EST - zacks.com
4 Stocks to Buy Amid Dental Supplies Industry Challenges
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
4 Stocks to Buy Amid Dental Supplies Industry Challenges
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
09/19 12:16 EST - zacks.com
BD Stock Rises as Neopak XtraFlow Syringe Expands in Biologics
BDX launches the Neopak XtraFlow Glass Prefillable Syringe, enhancing drug delivery for biologics and expanding capacity with new high-volume production lines.
BD Stock Rises as Neopak XtraFlow Syringe Expands in Biologics
BDX launches the Neopak XtraFlow Glass Prefillable Syringe, enhancing drug delivery for biologics and expanding capacity with new high-volume production lines.
09/18 06:50 EST - prnewswire.com
BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics
LE PONT-DE-CLAIX, France , Sept. 18, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform to serve the growing market for biologic therapies.
BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics
LE PONT-DE-CLAIX, France , Sept. 18, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform to serve the growing market for biologic therapies.
09/13 10:03 EST - seekingalpha.com
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market position in prefilled syringes and self-administered injection systems positions it to benefit significantly from the fast-growing GLP-1 market, potentially adding $1 billion in revenue by 2030. The acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion is expected to accelerate BDX's revenue growth and expand margins, enhancing its smart connected care solutions.
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market position in prefilled syringes and self-administered injection systems positions it to benefit significantly from the fast-growing GLP-1 market, potentially adding $1 billion in revenue by 2030. The acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion is expected to accelerate BDX's revenue growth and expand margins, enhancing its smart connected care solutions.
09/10 10:46 EST - zacks.com
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
09/09 10:50 EST - zacks.com
Here's Why Becton Dickinson (BDX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Becton Dickinson (BDX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
09/05 11:45 EST - zacks.com
BD Stock Falls After Acquisition of Edwards' Critical Care Group
BDX expands its smart care portfolio by acquiring Edwards Lifesciences' Critical Care group, now BD Advanced Patient Monitoring, strengthening AI-driven health solutions.
BD Stock Falls After Acquisition of Edwards' Critical Care Group
BDX expands its smart care portfolio by acquiring Edwards Lifesciences' Critical Care group, now BD Advanced Patient Monitoring, strengthening AI-driven health solutions.
09/04 15:51 EST - seekingalpha.com
Becton, Dickinson and Company (BDX) Wells Fargo 2024 Healthcare Conference
Becton, Dickinson and Company (NYSE:BDX ) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:45 AM ET Company Participants Tom Polen - Chairman, President & CEO Conference Call Participants Lawrence Biegelsen - Wells Fargo Lawrence Biegelsen Welcome back. Good morning.
Becton, Dickinson and Company (BDX) Wells Fargo 2024 Healthcare Conference
Becton, Dickinson and Company (NYSE:BDX ) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:45 AM ET Company Participants Tom Polen - Chairman, President & CEO Conference Call Participants Lawrence Biegelsen - Wells Fargo Lawrence Biegelsen Welcome back. Good morning.
09/03 16:30 EST - prnewswire.com
BD Completes Acquisition of Critical Care from Edwards Lifesciences
Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision tools Combination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilities Business renamed as BD Advanced Patient Monitoring, will be based in Irvine, Calif. and become part of BD Medical segment Katie Szyman will continue to lead BD Advanced Patient Monitoring as worldwide president FRANKLIN LAKES, N.J.
BD Completes Acquisition of Critical Care from Edwards Lifesciences
Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision tools Combination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilities Business renamed as BD Advanced Patient Monitoring, will be based in Irvine, Calif. and become part of BD Medical segment Katie Szyman will continue to lead BD Advanced Patient Monitoring as worldwide president FRANKLIN LAKES, N.J.
08/23 10:45 EST - zacks.com
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
08/22 13:00 EST - prnewswire.com
BD Celebrates 75 years of U.S. Manufacturing Excellence in Nebraska
Emphasizes Value of Domestic Production of Critical Medical Devices FRANKLIN LAKES, N.J. , Aug. 22, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrated the 75th anniversary of its manufacturing operations in Columbus, Neb.
BD Celebrates 75 years of U.S. Manufacturing Excellence in Nebraska
Emphasizes Value of Domestic Production of Critical Medical Devices FRANKLIN LAKES, N.J. , Aug. 22, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrated the 75th anniversary of its manufacturing operations in Columbus, Neb.
08/22 10:40 EST - zacks.com
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
08/21 10:50 EST - zacks.com
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
08/12 06:50 EST - prnewswire.com
BD Names Michael Feld as President of Life Sciences Segment
FRANKLIN LAKES, N.J. , Aug. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Michael Feld has been named executive vice president and president of the Life Sciences segment for BD, effective Aug. 20, 2024, and will serve as a member of the Executive Leadership Team.
BD Names Michael Feld as President of Life Sciences Segment
FRANKLIN LAKES, N.J. , Aug. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Michael Feld has been named executive vice president and president of the Life Sciences segment for BD, effective Aug. 20, 2024, and will serve as a member of the Executive Leadership Team.
08/10 07:00 EST - seekingalpha.com
10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next
Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the market decline might still have another 8%. Dividend aristocrats are down just 0.9% in this downturn, and many aristocrats are up modestly.
10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next
Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the market decline might still have another 8%. Dividend aristocrats are down just 0.9% in this downturn, and many aristocrats are up modestly.